Bicycle Therapeutics plc Earnings Per Share (Basic)
Bicycle Therapeutics plc (BCYC) reported Earnings Per Share (Basic) of -$0.72 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-07-30
- Bicycle Therapeutics plc earnings per share, basic for the quarter ending 2026-06-30 was -$0.72.
- Bicycle Therapeutics plc earnings per share, basic for the quarter ending 2026-03-31 was -$0.87.
- Bicycle Therapeutics plc earnings per share, basic for the quarter ending 2025-12-31 was -$0.29.
- Bicycle Therapeutics plc earnings per share, basic for the quarter ending 2025-09-30 was -$0.85.
- Bicycle Therapeutics plc earnings per share, basic for fiscal 2025 was -$3.16.
- Bicycle Therapeutics plc earnings per share, basic for fiscal 2024 was -$2.90.
- Bicycle Therapeutics plc earnings per share, basic for fiscal 2023 was -$5.08.
- Bicycle Therapeutics plc earnings per share, basic for fiscal 2022 was -$3.80.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$0.72 10-Q · filed 2026-07-30 | -$1.59 10-Q · filed 2026-07-30 | -$1.89 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$2.74 derived: net income ÷ weighted average shares · filed 2026-07-30 | |
| 2026-03-31 | -$0.87 10-Q · filed 2026-04-30 | -$1.16 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$2.02 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$3.16 derived: net income ÷ weighted average shares · filed 2026-07-30 | |
| 2025-12-31 | -$0.29 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$1.14 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$2.28 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$3.16 10-K · filed 2026-03-17 | |
| 2025-09-30 | -$0.85 10-Q · filed 2025-10-30 | -$1.99 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$2.87 10-Q · filed 2025-10-30 | -$3.62 derived: net income ÷ weighted average shares · filed 2026-07-30 | |
| 2025-06-30 | -$1.14 10-Q · filed 2026-07-30 | -$2.02 10-Q · filed 2026-07-30 | -$2.77 derived: net income ÷ weighted average shares · filed 2026-07-30 | -$3.51 derived: net income ÷ weighted average shares · filed 2026-07-30 | |
| 2025-03-31 | -$0.88 10-Q · filed 2026-04-30 | -$1.63 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$2.36 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$3.13 derived: net income ÷ weighted average shares · filed 2026-04-30 | |
| 2024-12-31 | -$0.75 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$1.49 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$2.25 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$2.90 10-K · filed 2026-03-17 | |
| 2024-09-30 | -$0.74 10-Q · filed 2025-10-30 | -$1.50 derived: net income ÷ weighted average shares · filed 2025-10-30 | -$2.15 10-Q · filed 2025-10-30 | -$3.23 derived: net income ÷ weighted average shares · filed 2026-03-17 | |
| 2024-06-30 | -$0.77 10-Q · filed 2025-08-08 | -$1.40 10-Q · filed 2025-08-08 | -$2.53 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$3.75 derived: net income ÷ weighted average shares · filed 2026-03-17 | |
| 2024-03-31 | -$0.62 10-Q · filed 2025-05-01 | -$1.78 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$3.02 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$4.34 derived: net income ÷ weighted average shares · filed 2026-03-17 | |
| 2023-12-31 | -$1.16 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$2.41 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$3.78 derived: net income ÷ weighted average shares · filed 2026-03-17 | -$5.08 10-K · filed 2026-03-17 | |
| 2023-09-30 | -$1.26 10-Q · filed 2024-10-31 | -$2.65 derived: net income ÷ weighted average shares · filed 2024-10-31 | -$3.95 10-Q · filed 2024-10-31 | -$4.99 derived: net income ÷ weighted average shares · filed 2025-02-25 | |
| 2023-06-30 | -$1.41 10-Q · filed 2024-08-06 | -$2.71 10-Q · filed 2024-08-06 | -$3.73 derived: net income ÷ weighted average shares · filed 2025-02-25 | -$4.68 derived: net income ÷ weighted average shares · filed 2025-02-25 | |
| 2023-03-31 | -$1.30 10-Q · filed 2024-05-02 | -$2.31 derived: net income ÷ weighted average shares · filed 2025-02-25 | -$3.27 derived: net income ÷ weighted average shares · filed 2025-02-25 | -$4.17 derived: net income ÷ weighted average shares · filed 2025-02-25 | |
| 2022-12-31 | -$1.01 derived: net income ÷ weighted average shares · filed 2025-02-25 | -$1.96 derived: net income ÷ weighted average shares · filed 2025-02-25 | -$2.87 derived: net income ÷ weighted average shares · filed 2025-02-25 | -$3.80 10-K · filed 2025-02-25 | |
| 2022-09-30 | -$0.96 10-Q · filed 2023-11-02 | -$1.86 derived: net income ÷ weighted average shares · filed 2023-11-02 | -$2.79 10-Q · filed 2023-11-02 | -$3.42 derived: net income ÷ weighted average shares · filed 2024-02-20 | |
| 2022-06-30 | -$0.90 10-Q · filed 2023-08-03 | -$1.84 10-Q · filed 2023-08-03 | -$2.46 derived: net income ÷ weighted average shares · filed 2024-02-20 | -$3.07 derived: net income ÷ weighted average shares · filed 2024-02-20 | |
| 2022-03-31 | -$0.93 10-Q · filed 2023-05-04 | -$1.55 derived: net income ÷ weighted average shares · filed 2024-02-20 | -$2.16 derived: net income ÷ weighted average shares · filed 2024-02-20 | -$2.90 derived: net income ÷ weighted average shares · filed 2024-02-20 | |
| 2021-12-31 | -$0.62 derived: net income ÷ weighted average shares · filed 2024-02-20 | -$1.21 derived: net income ÷ weighted average shares · filed 2024-02-20 | -$1.94 derived: net income ÷ weighted average shares · filed 2024-02-20 | -$2.67 10-K · filed 2024-02-20 | |
| 2021-09-30 | -$0.59 10-Q · filed 2022-11-03 | -$1.33 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$2.06 10-Q · filed 2022-11-03 | -$2.87 derived: net income ÷ weighted average shares · filed 2023-02-28 | |
| 2021-06-30 | -$0.74 10-Q · filed 2022-08-04 | -$1.48 10-Q · filed 2022-08-04 | -$2.30 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.85 derived: net income ÷ weighted average shares · filed 2023-02-28 | |
| 2021-03-31 | -$0.73 10-Q · filed 2022-05-05 | -$0.74 10-Q · filed 2021-08-05 | -$1.56 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.10 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.77 derived: net income ÷ weighted average shares · filed 2023-02-28 |
| 2020-12-31 | -$0.83 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$1.36 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.03 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.66 10-K · filed 2023-02-28 | |
| 2020-09-30 | -$0.52 10-Q · filed 2021-11-04 | -$1.19 derived: net income ÷ weighted average shares · filed 2021-11-04 | -$1.81 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | -$0.67 10-Q · filed 2021-08-05 | -$1.30 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | -$2.77 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |